The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Aetna CEO Warned It Would Cut Obamacare If Humana Deal Was Blocked

Aetna CEO Warned It Would Cut Obamacare If Humana Deal Was Blocked

August 18, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters)—Aetna Inc.’s CEO said in a letter to the U.S. Department of Justice (DOJ) during the review of its deal to buy rival Humana Inc that the insurer would exit much of the individual Obamacare insurance market if the agency challenged the merger.

You Might Also Like
  • U.S. Justice Department Has Concerns about Aetna-Humana Deal
  • Aetna’s Deal for Humana May Push Up Costs for Seniors
  • Aetna Pulls Back on Obamacare Health Insurance Plans in 2017

In the July 5 letter, Chief Executive Officer Mark Bertolini said it would be some time before the company recouped the investment it had made over the past 2 1/2 years in the government-subsidized insurance plans created under President Barack Obama’s national healthcare reform law.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Our ability to withstand these losses is dependent on our achieving anticipated synergies in the Humana acquisition,” Bertolini writes, according to a copy of the letter posted on the Huffington Post website, which obtained the document though the Freedom of Information Act.

“Unfortunately, a challenge by the DOJ to that acquisition and/or the DOJ successfully blocking the transaction would have a negative financial impact on Aetna and would impair Aetna’s ability to continue its support,” he writes.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

UnitedHealth Group Inc. and Humana Inc. have cited similar concerns about financial losses on the Obamacare exchanges and have also cut back most of their plans for 2017.

The DOJ moved on July 21 to block Aetna’s acquisition of Humana and Anthem Inc.’s purchase of Cigna Corp., saying the two deals would lead to higher prices.

Aetna on Monday announced it would pull out of selling individual insurance on the government-run websites in 11 states, saying its losses on the business were too high.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Aetna spokesman TJ Crawford says in an emailed statement that because the company submitted the letter to the DOJ, it had a better view of the business line’s second-quarter performance.

“That deterioration, and not the DOJ challenge to our Humana transaction, is ultimately what drove us to announce the narrowing of our public exchange presence for the 2017 plan year,” Crawford says.

Filed Under: Legal, Professional Topics Tagged With: Aetna Inc., Affordable Care Act, Health Insurance, Obamacare

You Might Also Like:
  • U.S. Justice Department Has Concerns about Aetna-Humana Deal
  • Aetna’s Deal for Humana May Push Up Costs for Seniors
  • Aetna Pulls Back on Obamacare Health Insurance Plans in 2017
  • U.S. Regulators Sue to Block Anthem-Cigna & Aetna-Humana Mergers

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)